247082-83-3

Usage

Uses

Used in Pharmaceutical Industry:
1-ACETYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID METHYL ESTER serves as a crucial intermediate in the synthesis of various pharmaceutical drugs. Its unique structure allows it to be a building block for the creation of new medicinal compounds, potentially leading to the development of innovative treatments for different diseases.
Used in Organic Chemistry Research:
In the realm of organic chemistry, 1-ACETYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID METHYL ESTER is utilized for research purposes. Its reactivity and structural features make it a valuable subject for studying reaction mechanisms, synthesis techniques, and the exploration of new chemical pathways.
Used in Natural Product Synthesis:
1-ACETYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID METHYL ESTER is also employed in the synthesis of natural products, contributing to the development of bioactive molecules that can be derived from or inspired by substances found in nature. Its use in this area can lead to the discovery of novel compounds with potential applications in medicine and healthcare.
Used in Drug Development:
1-ACETYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID METHYL ESTER holds promise in the development of new drugs for various medical conditions due to its potential biological activities. Its anti-inflammatory and antioxidant properties are of particular interest, as they may contribute to the treatment of conditions where these properties are beneficial.
While the specific applications and industries for 1-ACETYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID METHYL ESTER are not exhaustively detailed in the provided materials, the compound's role in pharmaceutical synthesis, organic chemistry research, natural product synthesis, and drug development indicates its broad utility and significance in the scientific and medical fields.

Upstream product

• 619-45-4 4-methoxycarbonyl aniline 
• 7270-63-5 5-diazo-2,2-dimethyl-1,3-dioxane-4,6-dion 
• 17012-22-5 methyl 4-acetamidobenzoate 
• 108-24-7 acetic anhydride 
• 199328-10-4 methyl 2-oxoindoline-5-carboxylate 

Downstream Products

• 247085-19-4 Methyl 1-acetyl-3-(1-ethoxy-1-phenyl-methylene)-2-indolinone-5-carboxylate 
• 1253769-05-9 (Z)-1-acetyl-3-(ethoxy-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of oxindole from acetanilide via Ir(iii)-catalyzed C-H carbenoid functionalization

Herein we disclose the first report on the synthesis of oxindole derivatives from acetanilide via Ir(iii)-catalyzed intermolecular C-H functionalization with diazotized Meldrum's acid. A broad range of substituted anilides were found to react smoothly under the Ir(iii)-catalytic system to afford the corresponding N-protected oxindoles. The N-protecting groups, such as Ac, Bz or Piv, can be easily removed to furnish the oxindole. Various synthetic applications of the synthesized oxindole were also demonstrated.

Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth

Despite recent advances in molecularly directed therapy, triple negative breast cancer (TNBC) remains one of the most aggressive forms of breast cancer, still without a suitable target for specific inhibitors. Maternal embryonic leucine zipper kinase (MELK) is highly expressed in TNBC, where level of overexpression correlates with poor prognosis and an aggressive disease course. Herein, we describe the discovery through targeted kinase inhibitor library screening, and structure-guided design of a series of ATP-competitive indolinone derivatives with subnanomolar inhibition constants towards MELK. The most potent compound, 17, inhibits the expression of the anti-apoptotic protein Mcl-1 and proliferation of TNBC cells exhibiting selectivity for cells expressing high levels of MELK. These studies suggest that further elaboration of 17 will furnish MELK-selective inhibitors with potential for development in preclinical models of TNBC and other cancers.

Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor i (TGFβRI)

Inhibition of transforming growth factor β (TGFβ) type I receptor (Alk5) offers a novel approach for the treatment of fibrotic diseases and cancer. Indolinones substituted in position 6 were identified as a new chemotype inhibiting TGFβRI concomitant with

Substituted indolinones with kinase inhibitory activity

Substituted indolinones of general formula having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. Exemplary compounds are: 3-Z-[1-(4-(N-Benzyl-N-methyl-aminomethyl)-phenylamino)-1-methyl-methylene]-5-a

Indolinones having kinase inhibitory activity

The present invention relates to substituted indolinones of general formula [Figure] wherein R1 to R5, and X are defined as in claim 1, the isomers thereof and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibitory effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these (compounds, their use and processes for preparing them.